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ABSTRACT
DNA binding by the ternary complex factor (TCF)
subfamily of ETS-domain transcription factors is
tightly regulated by intramolecular and intermolecu-
lar interactions. The helix±loop±helix (HLH)-contain-
ing Id proteins are trans-acting negative regulators
of DNA binding by the TCFs. In the TCF, SAP-2/Net/
ERP, intramolecular inhibition of DNA binding is
promoted by the cis-acting NID region that also con-
tains an HLH-like motif. The NID also acts as a
transcriptional repression domain. Here, we have
studied the role of HLH motifs in regulating DNA
binding and transcription by the TCF protein SAP-1
and how Cdk-mediated phosphorylation affects the
inhibitory activity of the Id proteins towards the
TCFs. We demonstrate that the NID region of SAP-1
is an autoinhibitory motif that acts to inhibit DNA
binding and also functions as a transcription
repression domain. This region can be functionally
replaced by fusion of Id proteins to SAP-1, whereby
the Id moiety then acts to repress DNA binding in
cis. Phosphorylation of the Ids by cyclin±Cdk com-
plexes results in reduction in protein±protein inter-
actions between the Ids and TCFs and relief of their
DNA-binding inhibitory activity. In revealing distinct
mechanisms through which HLH motifs modulate
the activity of TCFs, our results therefore provide
further insight into the role of HLH motifs in regulat-
ing TCF function and how the inhibitory properties
of the trans-acting Id HLH proteins are themselves
regulated by phosphorylation.
INTRODUCTION
Elk-1, SAP-1 and SAP-2/Net/ERP comprise the ternary
complex factor (TCF) subfamily of ETS-domain transcription
factors [reviewed in Treisman (1) and Sharrocks (2)]. These
proteins all exhibit the common property of being able to form
ternary complexes with the serum response factor (SRF) on
serum response elements (SREs). In addition, they all share
four regions of sequence similarity, the ETS DNA-binding
domain, the B-box SRF interaction motif, a mitogen-activated
protein (MAP) kinase docking site (D-domain) and a
C-terminal transcription activation domain which is the target
for MAP kinase-mediated phosphorylation. In addition to
ternary complex formation with SRF, the TCFs also exhibit
autonomous, SRF-independent DNA-binding activity to high
af®nity binding motifs. DNA binding by the TCFs is regulated
at many levels. DNA binding is enhanced following phos-
phorylation by MAP kinases (3±5), and interaction with SRF
also promotes DNA binding (6±9). Both of these regulatory
modes act to overcome autoinhibitory mechanisms that exist
to inhibit DNA binding (6,10,11). DNA binding by SAP-2/
Net/ERP is autoinhibited by the NID (Net inhibitory domain)
region (12). The NID was also shown to act as a transcriptional
repression domain, further emphasising its role as a negatively
acting element (12). Sequence comparisons and mutational
analysis suggest that this region adopts a helix±loop±helix
(HLH)-like structure (12). The NID is conserved in SAP-1 but
is absent in Elk-1.
In addition to cis-acting mechanisms, DNA binding by the
TCFs can also be inhibited in trans by interactions with
members of the Id family of HLH proteins (13). Inhibition is
mediated by direct interactions of the Ids with the ETS
DNA-binding domain of the TCFs. The HLH motif in the Id
proteins is crucial for these interactions (13) and exhibits
signi®cant sequence similarity with the HLH motif found
in the SAP-1 NID (see Fig. 4A). Id proteins are well known
for their ability to interact with, and to inhibit the DNA-
binding activity of a number of other transcription factor
families, of which the basic HLH (bHLH) proteins are best
characterised (14±17). The inhibitory properties of the Id
proteins on bHLH proteins are regulated through phosphoryl-
ation by cyclinA/E±cyclin-dependent kinase (Cdk) com-
plexes. Both Id2 and Id3 can be phosphorylated at Ser5, and
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this abrogates their ability to inhibit DNA binding by class A
bHLH E proteins (18,19).
Here we have investigated how HLH motifs act in cis and in
trans to regulate the activity of the TCFs. In common with
SAP-2/Net/ERP, the NID region of SAP-1 inhibits DNA
binding and also acts as a transcriptional repression domain.
Fusion of the Id proteins to SAP-1 functionally replaces the
NID and acts to repress DNA binding in cis. Phosphorylation
of the Ids results in a reduction in protein±protein interactions
between the Ids and TCFs and concomitant relief of their
DNA-binding inhibitory activity. Together, our results there-
fore provide further insights into the role of HLH motifs in
modifying the activities of the TCFs and how the inhibitory
properties of the trans-acting Id proteins are regulated.
MATERIALS AND METHODS
Plasmid constructs
The following plasmids were used to express GST fusion
proteins in Escherichia coli. pAS58 encodes coreSRF (amino
acids 132±222) fused to the C-terminus of GST. pAS919
[encoding Id2 (amino acids 1±134) fused to the N-terminus of
GST] was constructed by ligating an NcoI±SacI PCR fragment
encoding Id2 into the same sites in pETGEXCT (20).
pAS1562 and pAS1563 encode equivalent GST fusion
proteins with the Id2 mutants Ser5Ala and Ser5Asp, respect-
ively, and were constructed by PCR ampli®cation from
pCDNA3Id2Ala and pCDNA3Id2Asp (19), respectively,
using oligonucleotide primer pair ADS851±ADS632, and
ligated as NcoI±SacI fragments into the same sites of
pETGEXCT.
The following plasmids were used for expressing
C-terminal hexahistidine-Flag-tagged proteins in E.coli.
pAS278 encodes full-length Elk-1 (amino acids 1±428) (21).
pAS323 (constructed by Paul Shore) encodes the Elk-1 ETS-
domain (amino acids 1±93) and was constructed by ligating an
NcoI±XhoI PCR fragment into the same sites of pET-Hnef-
PFH (22). pAS1598 and pAS1600 encode SAP-1 (amino acids
1±157) fused to Id2 (amino acids 1±134) and Id3 (amino acids
1±119), respectively. To create these plasmids, a fragment of
SAP-1 (amino acids 1±157) was ampli®ed by PCR with the
primer pair ADS167±ADS850 on template pT7.SAP-1
(encoding full-length SAP-1; amino acids 1±431) (6) and
cloned as an NcoI±XbaI fragment into pAS37 (23) to create
pAS1561; Id2 and Id3 were ampli®ed by PCR from templates
pAS919 and pCDNA3Id3 (encoding full-length Id3; amino
acids 1±119) (24) using primer pairs ADS967±ADS968 and
ADS849±ADS969, respectively, followed by ligation as
NdeI±XbaI fragments into the same sites of pAS1561 to
create pAS1597 and pAS1599, respectively. SAP-1±Id2 or
SAP-1±Id3 fusions were excised from pAS1597 and pAS1599
with NcoI±XhoI and ligated into the same sites of pET-Hnef-
PFH to create pAS1598 and pAS1600, respectively. pAS1918
and pAS1919 encode Elk-1 ETS-domain and SAP-1 ETS-
domain, respectively, with C-terminal hexahistidine ¯ag tags,
on a polycistronic plasmid with Id2. First, Id2 was ampli®ed
from pAS919 with primer pair ADS967±ADS970, cloned as
an NdeI±BamHI fragment into pET3aTr (25), and transferred
as an XbaI±BamHI fragment into pST39 (25) to create
pAS1917. Next, the SAP-1 ETS-domain (amino acids 1±92)
was ampli®ed from pT7.SAP-1 with primer pair ADS972±
ADS974 and cloned into NcoI±XhoI sites of pET-Hnef-PFH
to create pAS1905. Similarly, the Elk-1 ETS-domain (amino
acids 1±93) was ampli®ed from pAS278 using primer pair
ADS973±ADS975 and cloned as an NdeI±XhoI fragment into
pAS1905 to create pAS1904. The SAP-1 and Elk-1 ETS-
domains with C-terminal hexahistidine ¯ag tags were excised
from pAS1904 and pAS1905 with NdeI±BamHI and cloned
into the same sites of pET3aTr to create pAS1907 and
pAS1906; then cloned as SacI±KpnI fragments from pAS1907
and pAS1906 into pAS1917 (pET3aTr containing Id2) to
create pAS1919 and pAS1918, respectively.
The following plasmids were used for in vitro transcription/
translation purposes. pAS136 encoding SAP-1(1±92) and
pAS168 encoding SAP-1(1±157) have been described pre-
viously (26). pAS1552, pAS1589, pAS1590 and pAS1591
encode SAP-1 truncations (amino acids 1±214, 1±197, 1±181
and 1±172, respectively). pAS1552 was constructed by
inserting an NcoI±SalI-cleaved PCR product (primers;
ADS167±ADS655 on template pT7.SAP-1) into the NcoI±
XhoI sites of pAS728 (encoding full-length Elk-1; amino
acids 1±428) (27). pAS1589, pAS1590 and pAS1591 were
constructed by ligating NcoI±XbaI-cleaved PCR-derived
fragments (primer pairs ADS167±ADS934, ADS167±
ADS935 and ADS167±ADS933, respectively, on pAS1552
template) into the same sites of pAS37. pAS1571 (encoding
Elk-1; amino acids 1±225) was constructed by ligating NcoI±
XbaI-cleaved PCR products (primers ADS106±ADS900 and
pAS278 template) into the same sites of pAS37. pAS1584 and
pAS1583 encode Elk-1(1±168)±SAP-1(158±214) and Elk-
1(1±168)±SAP-2(153±209) hybrids, respectively. Elk-1
(amino acids 1±168) was ampli®ed from pAS278 with primer
pair ADS106±ADS898, cleaved with NcoI±XbaI, and ligated
into the same sites of pAS37 to create pAS1572. SAP-1 amino
acids 158±214 and SAP-2 amino acids 153±209 were
ampli®ed by PCR [primers ADS901±ADS830 on template
pT7.SAP-1, and primers ADS902±ADS903 on template
pT7.SAP-2 (encoding full-length SAP-2; amino acids 1±
407) (28), respectively], and the resulting fragments were
cleaved with NdeI±XbaI and cloned into the same sites of
pAS1572 to create pAS1584 and pAS1583, respectively.
pAS2007 encodes SAP-1(158±214), and was constructed by
inserting a HindIII±XbaI-cut PCR fragment (primers
ADS847±ADS830 on pT7.SAP-1 template) into the same
sites of pAS37. pAS1859 [encoding SAP-1(1±214)(K191P)],
pAS1861 [encoding SAP-1(1±214)(K165P)] and pAS1862
[encoding SAP-1(1±214)(K165P/K191P)] were constructed
by two-step PCR [¯anking REV and FOR and mutagenic
ADS1104, ADS1114 and ADS1114 primers, respectively, on
templates pAS1552 (to create K165P and K191P mutants) and
pAS1859 (to create K165P and K191P mutants) followed by
cleavage with NcoI±XbaI and insertion into the same sites of
pAS37]. pAS1560 encodes full-length Id2 (amino acids 1±
134), and was constructed by inserting an NcoI±SacI-cleaved
PCR fragment (primers ADS633±ADS846 on template
pAS919) into the same sites of pAS37. pAS1565 encodes
SAP-1(1±157)±Id3 hybrid, and was constructed by insertion
of an NdeI±XbaI-cleaved PCR product encoding full-length
Id3 (amino acids 1±119) (primers ADS849±ADS848
on template pCDNA3Id3), and ligation into the same
sites of pAS1561 (containing SAP-1 amino acids 1±157).
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pcDNA3-Id3Ala and pCDNA3-Id3Asp contain full-length Id3
(amino acids 1±119) with Ser5Ala and Ser5Asp mutations,
respectively, and have previously been described (19).
The following plasmids were used in mammalian cell
transfections. pG5tkluc (pAS1567) contains ®ve GAL4 DNA-
binding sites cloned upstream of a minimal TK promoter
element and the luciferase reporter (29). The L8G5E1a-Luc
and LexA-VP16 constructs were provided by C. Lemercier
(30). pSRE-luc (13) and pRSV-ElkVP16 (28) have been
described previously. pAS571 (pCMV-GAL) has been
described previously (29). pAS1901 (constructed by Shen-
Hsi Yang) encodes SAP-1 (amino acids 1±157) fused to the
GAL4 DNA-binding domain under the control of a cyto-
megalovirus (CMV) promoter, and was constructed by
ligating a SalI±XbaI PCR fragment into the same sites of
pAS571. pAS1555 and pAS1554 encode SAP-1 (amino acids
158±214 and 215±316, respectively) fused to the GAL4 DNA-
binding domain under the control of a CMV promoter; they
were constructed by ligating a SalI±XbaI-cleaved PCR
product (primers ADS829±ADS830 and ADS816±ADS817,
respectively, on pT7.SAP-1 template) into the same sites of
pAS1079 (newpCMV5-GAL4). pAS1079 was created by
cloning the HindIII±XbaI fragment from pAS1068 (31) into
the same sites of pCMV5. pAS383 (CMV-driven Elk-1 amino
acids 1±428 and C-terminal Flag tag) (21), pcDNA3Id2 (24),
pCDNA3Id2Ala and pCDNA3Id2Asp have previously been
described (19).
All PCR-derived constructs were veri®ed by automated
dideoxy sequencing.
Protein expression
The synthesis of proteins by in vitro transcription and
translation was carried out with the TNT-coupled reticulocyte
lysate system (Promega) according to the manufacturer's
recommendations. Newly synthesised 35S-labelled proteins
were analysed by SDS±PAGE followed by visualisation and
quanti®cation by phosphoimager analysis (Bio-Rad molecular
imagerâFX and Quantity One software). GST fusion proteins
(32) and hexahistidine-tagged proteins (21) were expressed in
E.coli BL21(DE3)(pLysS) and puri®ed as described pre-
viously. The purity and concentration of proteins were
determined by SDS±PAGE next to standards. To purify Id±
TCF complexes, Id2 and TCF ETS-domain (HisFlag-tagged)
were co-expressed in E.coli BL21(DE3)(pLysS) transformed
with a single plasmid (pAS1918 and pAS1919 encode Elk-1
ETS-domain and SAP-1 ETS-domain with C-terminal hexa-
histidine ¯ag tag, respectively, on a polycistronic plasmid with
Id2). Cells were grown in 0.5 l of LB/Amp medium at 37°C to
mid-log phase, then induced with isopropyl-b-D-thiogalacto-
pyranoside (IPTG) at a ®nal concentration of 0.1 mM at 30°C
for 2 h. Cells were harvested, resuspended in 5 ml of buffer A
[50 mM HEPES pH 7.9, 150 mM NaCl, 4 mM phenylmethyl-
sulfonyl ¯uoride (PMSF), 1.4 mM b-mercaptoethanol, 10%
glycerol] and sonicated for 4 3 8 s with 20 s intervals on ice.
The supernatant was cleared by centrifugation (10 000 g,
10 min) and applied to 300 ml of Ni2+-NTA±agarose (Qiagen)
equilibriated in buffer A. Binding was carried out at 4°C for
1.5 h. Beads were then washed three times with buffer B
(buffer A plus 15 mM imidazole). Protein was eluted with
300 ml of buffer C (buffer A plus 250 mM imidazole), and
subsequently dialysed overnight into buffer A.
In vitro protein±protein interaction assays
Interactions between GST- or His-tagged fusion proteins and
in vitro-translated or His-tagged proteins were investigated
using pull-down assays as described previously (33).
Gel retardation assays
Gel retardation assays were performed with 32P-labelled
probes as described previously (34). The binding sites include
the c-fos SRE and the E74 site (33). DNA±protein complexes
were formed at room temperature for 15 min. Proteins used
included bacterially expressed coreSRF and bacterially expres-
sed or in vitro-translated TCF and Id derivatives. Reactions
containing in vitro translated proteins were normalised for
reticulocyte lysate content. Complexes were analysed on non-
denaturing 5% polyacrylamide gels cast in 0.53 Tris±borate±
EDTA and visualised by phosphoimager analysis.
Cell culture transfection and reporter gene assays
293 cells were maintained in Dulbecco's modi®ed Eagle's
medium (DMEM) supplemented with 10% fetal bovine serum
(FBS) (Gibco-BRL). Duplicate transfection experiments were
done in 6-well plates using polyfect reagent according to the
manufacturer's recommendations (Qiagen). For reporter gene
assays, SRE and GAL4 promoter-driven reporters were co-
transfected alongside vectors encoding Elk-VP16 and GAL4-
SAP-1 fusions, respectively. DNA concentrations were nor-
malised with empty pCMV5 vector. Cell extracts were
prepared, and luciferase and b-galactosidase assays were
carried out as described previously (21).
Protein phosphorylation
Kinase reactions were carried out as described previously;
Elk-1 was phosphorylated by ERK (21); Id was phosphoryl-
ated by cyclinA±Cdk2 (19). Mock reactions were done as per
phosphorylation reactions, with the omission of kinase.
Immunoprecipitations and western blotting
For in vitro immunoprecipitations, Id2 and Elk-1(1±93)-
HisFlag were co-expressed in bacteria and puri®ed on Ni2+-
NTA±agarose. Eluted, dialysed protein (1 mg) was used in
20 ml reactions containing 1 mMDTT, 0.05 mMATP, 0.1 mM
Na3VO4, plus or minus 0.5 ml of cyclinA±Cdk2 kinase, and
incubated at 37°C for 30 min. Protein G beads (20 ml) were
equilibriated in buffer A, then coupled to 0.5 ml of Id2
antibody for 1 h at room temperature. Beads were washed
three times in buffer A to remove non-associated antibody.
Following phosphorylation or mock treatment, Id2 and Elk-
1(1±93) complexes were then added to beads coupled to
antibody, and left to bind at room temperature for 1.5 h. Non-
speci®c interactions were subsequently removed by washing
three times with buffer A. Bound Elk-93 was detected by
western blotting with an anti-Flag antibody.
For in vivo immunoprecipitations, a total of 15 mg of DNA
[e.g. 7.5 mg of pAS383 (Flag-tagged Elk-1) and 7.5 mg of
pcDNA3-Id2 (WT)] was transfected into 293T cells in 6-well
plates using the standard calcium phosphate precipitation
method. Cells were harvested 24 h later, rinsed in phosphate-
buffered saline (PBS) and a cell lysate was prepared by the
two-step lysis method in a total volume of 0.5 ml, essentially
as described previously (35). Immunoprecipitations were
Nucleic Acids Research, 2003, Vol. 31, No. 16 4719
 at U
n
iv
ersity
 o
f N
ew
castle o
n
 M
arch
 8
, 2
0
1
2
h
ttp
://n
ar.o
x
fo
rd
jo
u
rn
als.o
rg
/
D
o
w
n
lo
ad
ed
 fro
m
 
carried out in the presence of 2 mg of Flag M2 antibody
(Sigma) and 10 ml of protein G±Sepharose (Amersham-
Pharmacia) for 12 h at 4°C with gentle mixing. Immune
complexes were washed three times in lysis buffer [20 mM
Tris±HCl pH 7.4, 420 mM NaCl, 10 mM MgCl2, 2 mM
EDTA, 10% glycerol, 1% Triton X-100, 25 mM b-
glycerophosphate, 10 mM NaF, 1 mM DTT and completeÔ
protease inhibitors (Roche)], then eluted by boiling in SDS-
sample buffer and subjected to 15 or 10% SDS±PAGE for the
detection of Id2 or Elk-1 (Flag), respectively. Proteins were
blotted onto nitrocellulose membranes and incubated with Id2
antibody (Santa Cruz, 1:100 in 3% skimmed milk/TBS) or
Flag M2 antibody (1:2000) and then horseradish peroxidase
(HRP)-conjugated anti-rabbit IgG (DAKO, 1:2000) or anti-
mouse IgG (Sigma: 1:2000), and visualised by ECL
(Amersham-Pharmacia). Equal loading of lysate was con-
®rmed by Coomassie brilliant blue staining (data not shown).
Id3 and GAL4 antibodies for western blotting were
obtained from Santa Cruz.
Figure generation
Figures were generated from images generated by Molecular
ImagerâFX, Fluor-SÔ MultiImager and Quantity One soft-
ware (Bio-Rad). Final ®gures were assembled using
PowerPoint 7.0 software (Microsoft).
RESULTS
The NID of SAP-1 represents a DNA-binding inhibitory
element and transcriptional repression domain
Studies on SAP-2/Net/ERP have demonstrated that a region
downstream from the B-box region, the NID, acts to inhibit
DNA binding in vitro and also to repress transcription in vivo
Figure 1. The SAP-1 NID has a DNA-binding autoinhibitory function. (A) Schematic diagram of SAP-1 domains illustrating regions contained in truncated
SAP-1 proteins. Numbers in brackets indicate N- and C-terminal amino acid residues of truncations, with respect to full-length protein. (B) Gel retardation
analysis of binary (2o) and ternary (3o) complex formation by SAP-1(1±92) (lanes 2±6), SAP-1(1±157) (lanes 7±11) or SAP-1(1±214) (lanes 12±16) with
coreSRF and c-fos SRE. The locations of binary SRF±DNA complexes are indicated. In vitro translated SAP-1 truncations were diluted to equal molar concen-
trations, and increasing volumes were added (0.2, 0.6, 1, 1.4 and 1.8 ml). (C) Binary (2o) complex formation of SAP-1 truncations on c-fos SRE as in (B)
except SRF was omitted. (D) Gel retardation analysis of binary complexes on the E74-binding site by SAP-1 truncations: SAP-1(1±157) (lanes 1±3), SAP-
1(1±214) (lanes 4±6), SAP-1(1±197) (lanes 7±9), SAP-1(1±181) (lanes 10±12) and SAP-1(1±172) (lanes 13±15). SAP-1 proteins were diluted to equal molar
concentrations, and 0.25 ml was used in lanes 1, 4, 7, 10 and 13; 0.75 ml in lanes 2, 5, 8, 11 and 14; and 2.25 ml in lanes 3, 6, 9, 12 and 15.
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(12). This region exhibits signi®cant sequence conservation in
SAP-1 (see Fig. 4A); therefore, we tested whether it was also
functionally conserved in this protein.
First we created a series of C-terminally truncated SAP-1
derivatives and assayed their DNA-binding characteristics.
Ternary complexes were observed on the SRE in combination
with SRF for both SAP-1(1±157) and SAP-1(1±214) (Fig. 1B,
lanes 7±16). However, binding by SAP-1(1±214) (that con-
tains an intact NID) was weaker than for SAP-1(1±157) (that
lacks the NID). As expected, weak SRF-independent binding
of SAP-1 was observed upon truncation of the B-box region
(Fig. 1B, lanes 2±6) (6). The ability of the same proteins to
bind the SRE in the absence of SRF was also tested (Fig. 1C).
In comparison with SAP-1(1±92), SAP-1(1±157) bound with a
reduced af®nity, due to the presence of the B-box (Fig. 1C)
(6). However, binding was barely detectable for SAP-1(1±
214), demonstrating an important role for the NID region in
inhibiting DNA binding (Fig. 1C, lanes 12±16). To further
investigate the requirements for autoinhibition of DNA
binding, further C-terminal deletions were tested on the high
af®nity E74 site (Fig. 1D). These deletion endpoints fall
within putative structural features found within the NID
(Fig. 4A). Upon deletion of the C-terminal residues of the
NID, enhanced DNA binding was observed. Sequential
deletion to amino acid 197 (to the end of putative helix 2)
and 181 (that lacks part of this helix) led to a stepwise
enhancement of DNA binding (Fig. 1D, lanes 4±12). This
DNA binding was not increased further upon truncation to
amino acid 172 (that lacks all helix 2; Fig. 1D, lanes 13±15).
Collectively, these data point to an important role for the NID
in inhibiting DNA binding by SAP-1 that is particularly
noticeable at sites where binding occurs in an SRF-
independent manner. Disruption of the structural integrity of
the putative HLH motif in the NID abrogates this inhibitory
function.
A series of GAL4 fusion proteins with portions of SAP-1
were created to assess the potential role of the NID as a
transcriptional repression domain (Fig. 2). GAL fusions to
both SAP-1(1±157) and SAP-1(158±214) exhibited strong
repressive activity on a TK-luc reporter construct in compari-
son with SAP-1(215±316) (Fig. 2A). The level of reporter
activity in the presence of GAL-SAP(158±214) was well
below that observed with the reporter alone, demonstrating
that the GAL fusion protein must be tethered to the DNA and
therefore that the NID does not inhibit DNA binding in this
context. Western blotting demonstrates that all constructs
Figure 2. The SAP-1 NID is a transcriptional repression domain. (A) The GAL4 DNA-binding domain (amino acids 1±147) was fused to a series of truncated
SAP-1 proteins (amino acids are shown in brackets). Cells were co-transfected with 1 mg of pG5tkluc reporter vector, 0.5 mg of pCH110 and 0.1 mg of either
pCMV alone (lane 1), pCMVGAL (lane 2), pCMVGAL-SAP-1(1±157) (lane 3), pCMVGAL-SAP-1(158±214) (lane 4), or pCMVGAL-SAP-1(215±316) (lane
5). Data presented are normalised with respect to b-gal activity, and values are given relative to control plasmid (taken as 1). Protein expression levels in
30 ml whole-cell extracts of transfected cells were determined by western analysis, using GAL4-speci®c antibodies. (B) GAL±SAP-1 truncations were tested
for repression function using a LexA-VP16-activated LexA-GAL4-luc reporter. 293 cells were transfected with 1 mg of L8G5E1aluc reporter, 0.5 mg of
pCH110 and either 0.2 mg of LexA-VP16 (lanes 2±5) or empty plasmid (lane 1) in addition to 0.1 mg of either pCMVGAL (lane 3), pCMVGAL-SAP-1(1±
157) (lane 4) or pCMVGAL-SAP-1(158±214) (lane 5). Data presented are normalised with respect to b-galactosidase activity, and values are given relative to
control plasmid (taken as 1). Protein expression levels were determined by western analysis of 10 ml of protein extract using GAL4-speci®c antibodies.
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were expressed to similar levels. SAP-1(1±157) contains the
ETS DNA-binding domain which has previously been shown
to act as a potent repression domain in the related protein, Elk-
1 (29), whereas SAP-1(158±214) just contains the NID. To
establish whether the SAP-1 NID could repress highly active
transcription, we analysed the ability of GAL-SAP-1 fusion
proteins to repress a luciferase reporter gene driven by
composite LexA- and GAL-binding sites (Fig. 2B) (30).
Constructs encoding LexA-VP16 fusion proteins were trans-
fected to activate the reporter gene, and GAL fusion proteins
were co-transfected to assess transcriptional repressive
properties. The GAL4 DNA-binding domain alone cooperated
with Lex-VP16 to give enhanced reporter activity. However,
GAL fusions with SAP-1(1±157) and SAP-1(158±214) both
resulted in substantial repression of reporter activity. Thus, the
SAP-1 NID appears to be a potent transcriptional repression
domain that can also act in trans to inhibit transcription.
In summary, the NID in SAP-1 appears to act in an
analogous manner to the NID in SAP-2/Net/ERP, to cause
inhibition of DNA binding and provide transcriptional
repression activities.
The SAP-1 NID represses DNA binding in trans and in
heterologous contexts
Deletion analysis indicated that the SAP-1 NID plays an
important role in regulating its DNA-binding activity. To
investigate whether the NID was suf®cient for inhibiting DNA
binding and whether the effect was context dependent, we ®rst
tested the role of the NID in inhibiting DNA binding when
fused to Elk-1 (Fig. 3A). The ability of Elk-1 derivatives to
bind DNA in the absence or presence of fusion to the NIDs
from SAP-1 and SAP-2 was compared (Fig. 3B). Fusion of the
NID from SAP-2 had a moderate effect in inhibiting DNA
binding by Elk-1 that is most apparent at lower protein
concentrations (Fig. 3B; compare lanes 2 and 10). This is
consistent with previous results with similar chimeric Elk-1±
SAP-2 proteins (12). However, fusion of the NID from SAP-1
resulted in potent inhibition of DNA binding (Fig. 3B, lanes 5±
8). Similar effects are seen on the binding of Elk-1 in ternary
complexes with SRF and the SRE (data not shown).
The Id proteins contain a helix±turn±helix motif that is
related to the NID sequence (Fig. 4A) and inhibits DNA
binding by TCF family members when added in trans (13;
Fig. 3C, lanes 6±9). This effect is elicited through the ETS
DNA-binding domain. We therefore tested whether the NID
could act in an analogous manner when added in trans.
Addition of increasing concentrations of the SAP-1 NID
[SAP-1(158±214)] led to a dose-dependent decrease in
DNA binding by the SAP-1 ETS-domain [SAP-1(1±92)]
(Fig. 3C lanes 2±5). Thus, the SAP-1 NID can act both in trans
and in cis to inhibit DNA binding through the SAP-1
ETS-domain.
Figure 3. The NID inhibits DNA binding in trans and in a heterologous
context. (A) Schematic diagram of SAP-1 domains illustrating regions
contained in full-length Elk-1, SAP-1 and SAP-2 proteins. Gaps are
introduced to permit alignment of the conserved regions. The structures of
the isolated domains used and chimeric Elk-1±NID constructs are indicated
below (numbers in brackets indicate N- and C-terminal amino acid residues
of truncations, with respect to full-length proteins). (B) Gel retardation
analysis of the indicated wild-type and chimeric Elk-1 proteins on the E74-
binding site. In vitro translated proteins were diluted to equal molar
concentrations, and added in increasing amounts (0.2, 0.6, 1.8 and 5.4 ml)
(indicated schematically above each set of lanes by a triangle). (C) SAP-1
NID inhibits binding of the SAP-1 ETS domain to the c-fos SRE in trans.
In vitro translated SAP-1 NID and Id2 were diluted to equal molar amounts,
and 0.5, 1, 2 and 4 ml (indicated schematically above each set of lanes by a
triangle) were added in the presence of a constant amount of SAP-1(1±92).
Total amounts of reticulocyte lysate were equalised by adding
unprogrammed lysate.
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Id proteins can inhibit DNA binding in cis
The Id proteins exhibit signi®cant sequence similarity to the
NID found in SAP-1 and SAP-2 (Fig. 4A), and the NID can act
in trans to inhibit DNA binding by the TCFs in an analogous
manner to the Id proteins. We therefore tested whether Id
proteins could functionally replace the NID in SAP-1 and
inhibit DNA binding in cis when fused to SAP-1 (Fig. 4B). In
the presence of the SAP-1 NID [SAP-1(1±214)], DNA binding
was severely inhibited (Fig. 4C, lanes 4±6). Fusion of Id3 to
the C-terminus of SAP-1(1±157) also resulted in inhibition of
DNA binding. This inhibition was even more pronounced than
that observed in SAP-1(1±214) (Fig. 4C, lanes 7±9). Similarly,
the fusion of Id2 to SAP-1 in the SAP-1(1±157)±Id2 protein
results in inhibition of ternary complex formation by SAP-1
and SRF on the SRE (data not shown). Deletions into the
C-terminus of the Id3 HLH motif, which are predicted to
affect its structural integrity, result in reduced DNA binding
inhibition (data not shown).
Our results suggest that the SAP-1 NID is structurally and
functionally related to the HLH motif (Figs 1, 3 and 4C). To
con®rm this conclusion, we introduced helix-breaking proline
residues into the putative helices in the context of the intact
NID (Fig. 4A). We then tested the resulting mutant proteins
[SAP-1(1±214)(K191P), SAP-1(1±214)(K165P) and SAP-
1(1±214)(K165P/K191P)] in comparison with their wild-
type counterparts for binding to the E74 site (Fig. 4D). In
comparison with the wild-type protein, enhanced DNA
binding was observed for SAP-1(1±214)(K165P) and SAP-
1(1±214)(K191P) (Fig. 4D, lanes 4±9). This binding was
further enhanced upon simultaneous introduction of the
two mutations in SAP-1(1±214)(K165P/K191P) (Fig. 4D,
Figure 4. Id proteins can functionally replace the NID. (A) Alignment of the sequences of the SAP-1 and SAP-2 NID domains, and the HLH domain of Id2.
The N- and C-terminal amino acid residues with respect to full-length protein are indicated. Arrows indicate the positions of insertion of proline residues in
the SAP-1(1±214) (K165P) and (K191P) mutants. (B) Schematic diagram of chimeric SAP-1 constructs used in (C) and (D). (C and D) Gel retardation analy-
sis of the indicated SAP-1 fusion proteins on the E74-binding site. In vitro translated proteins were normalised to equal molar concentrations, and added in
increasing relative amounts (1, 2.5 and 6) (C) and (1, 2 and 4) (D) (indicated schematically above each set of lanes by a triangle).
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lanes 10±12). Thus autoinhibition of DNA binding was lost in
these mutants. A difference in complex mobility was also
observed in these mutants, which is consistent with the
expected conformational change upon insertion of proline
residues. These data are consistent with the effects seen upon
introduction of a proline residue into the related NID motif in
SAP-2/Ner/Erp (12).
Thus, our data further support the conclusion that the NID is
structurally related to the HLH motif and that the NID and Id
proteins can act both in trans and in cis to inhibit DNA binding
by SAP-1.
Control of Id-regulated DNA binding inhibition by
Cdk-mediated phosphorylation
The Id2 and Id3 proteins are phosphorylated in vivo by cyclin±
Cdk2 complexes in a cell cycle-dependent manner. This
phosphorylation event occurs exclusively at a conserved Ser5
residue in the Id2/Id3 proteins and regulates their ability to
interact with bHLH transcription factors (18,19). We therefore
tested whether phosphorylation of Id2/3 proteins by cyclinA±
Cdk2 complexes affected their ability to inhibit DNA binding
by TCF ETS-domain transcription factors.
First, we tested the effect of phosphorylation on the
inhibitory actions of Id proteins in the context of SAP-1(1±
157)±Id2 fusion proteins. Phosphorylation of SAP-1(1±157)±
Id2 by cyclinA±cdk2 complexes led to an increase in DNA
binding by SAP-1(1±157)±Id2 in the context of ternary
complexes containing SRF (Fig. 5B) and also when binding
in the absence of SRF (Fig. 5C). Similar results were seen with
fusions with Id3 (data not shown).
Next we examined whether phosphorylation of Ids also
affected their ability to inhibit DNA binding in trans.
Polyhistidine-tagged ETS DNA-binding domains of Elk-1
[Elk-1(1±93)] or SAP-1 [SAP-1(1±92)] were co-expressed in
bacteria with Id2 to permit the formation of complexes upon
folding (25). Resulting ETS-domain±Id complexes were then
puri®ed by nickel af®nity chromatography, eluted and
tested for their DNA-binding activity either in the absence
of phosphorylation or following cyclinA±Cdk2-mediated
phosphorylation. If phosphorylation leads to the disruption
of the inhibitory properties of the Id proteins, it would be
predicted that enhanced DNA binding by the ETS-domain
should be observed. In the absence of phosphorylation of the
Elk-1(1±93)±Id2 complex, very low levels of DNA binding by
Elk-1(1±93) are observed (Fig. 5E, lanes 1±3). However, prior
phosphorylation through cyclinA±Cdk2 results in enhanced
DNA binding by Elk-1(1±93) (Fig. 5E, lanes 4±6). Similarly,
treatment of SAP-1(1±92)±Id2 complexes with cyclinA±Cdk2
results in enhanced DNA binding by SAP-1(1±92) (Fig. 5E,
lanes 7±12).
Collectively, these data demonstrate that phosphorylation
of Id proteins by cyclinA±Cdk2 complexes results in reduction
of the DNA-binding inhibitory capacity of the Ids when acting
either in cis or in trans.
Id phosphorylation inhibits interactions with TCFs
in trans
The loss of Id-mediated DNA binding inhibition caused by
phosphorylation probably re¯ects a change in the interactions
between the Id proteins and TCFs. To establish whether this is
the case, we investigated the effect of phosphorylation of Id
Figure 5. Phosphorylation of Id reduces its DNA-binding inhibitory
properties. (A) Schematic diagram of the chimeric SAP-1±Id2 construct.
The location of the cyclinA±Cdk2 phosphorylation site (Ser5) is indicated.
(B) Gel retardation analysis of SAP-1±Id2 chimeras in the absence and
presence of prior phosphorylation by cyclinA±Cdk2 complexes. The SAP-
1±Id2 chimeric protein was expressed in bacteria and puri®ed. SAP-1±Id2
was either left unphosphorylated or was phosphorylated by cyclinA±Cdk2.
Increasing amounts (24, 48 and 96 ng) were tested in a gel retardation assay
for effects on ternary (3o) complex formation with coreSRF and c-fos SRE.
(C) As in (B), except SRF was omitted from the reaction, the E74-binding
site was used, and binary (2o) complexes detected. SAP-1±Id2 was added at
12, 24, 48 and 96 ng (indicated schematically above each set of lanes by a
triangle). The asterisk represents a complex formed from truncated SAP-1±
Id protein. (D) Methodology for co-expressing Id2 and the ETS DNA-
binding domain of TCFs. Id2 and either the Elk-1 or SAP-1 ETS-domain
were co-expressed in E.coli from a single plasmid. Induced protein
complexes were puri®ed, and used in subsequent experiments.
(E) Complexes containing Id2 and the ETS-domain of either Elk-1 or
SAP-1 were either left unphosphorylated or phosphorylated with cyclinA±
Cdk2, and tested for their ability to bind to the c-fos SRE in gel retardation
analysis. Aliquots of 9.5 (lanes 1 and 4), 19 (lanes 2 and 5) and 57 ng
(lanes 3 and 6) of Elk-1(1±93)±Id2 complexes, and 15 (lanes 7 and 10), 30
(lanes 8 and 11) and 90 ng (lanes 9 and 12) of SAP-1(1±157)±Id2
complexes were added.
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proteins on interactions with the TCFs. First, we probed the
ability of cyclinA±Cdk2 to promote dissociation of pre-
formed complexes between the ETS-domain of Elk-1 and Id2.
Id2±Elk-1(1±93) complexes were puri®ed, treated with
cyclinA±Cdk2 and the resulting Id2-associated complexes
re-precipitated using Id2-speci®c antibodies (Fig. 6A). In
comparison with the non-phosphorylated samples, reduced
binding of Elk-1 was observed following cyclinA±Cdk2-
mediated phosphorylation of Id2±Elk-1(1±93) complexes
(Fig. 6A, lanes 3 and 4). Similar results were obtained by
carrying out reciprocal immunoprecipitations with anti-Flag
antibody, followed by detection of Id2 in the resulting
complexes (data not shown). These results are consistent
with the enhanced DNA-binding activity observed following
cyclinA±Cdk2-mediated phosphorylation of Id2/Elk-1(1±93)
complexes (Fig. 5E).
Interactions between Id2 and Elk-1 were also investigated
using GST pull-down analysis. Firstly, Id2±GST fusion
proteins were tested for interactions with Elk-1(1±93). Id2±
GST±Elk-1(1±93) complexes were detectable in the absence
of prior Id2 phosphorylation (Fig. 6B, lane 2). However,
phosphorylation of Id2±GST by cyclinA±Cdk2 led to a large
decrease in complex formation with Elk-1(1±93) (Fig. 6B,
lane 3). Next, we compared the interaction of full-length Elk-1
with Id2±GST. In this case, we also investigated the role of
Elk-1 phosphorylation by Erk2 in regulating these inter-
actions. Phosphorylation of Id2±GST led to decreases in
interactions with both phosphorylated and non-phosphoryl-
ated Elk-1 (Fig. 6C, compare lanes 1 and 5 with 2 and 6).
However, residual binding to non-phosphorylated Elk-1 was
observed that is further reduced upon Elk-1 phosphorylation,
adding a further tier of regulation on these interactions
(Fig. 6C, lanes 2 and 6).
In summary, interactions between Id proteins and Elk-1 are
reduced following phosphorylation of Ids with cyclinA±Cdk2.
This reduction in protein±protein interactions is consistent
with the reductions observed in the inhibitory activity of the
Ids towards the TCFs.
Phosphomimetic residues mimic the effect of
phosphorylation on Id±TCF interactions in vitro and
in vivo
To further establish the importance of Ser5 in Id proteins for
regulating interactions with TCFs, we analysed the effect of
introducing alanine (to block phosphorylation) or aspartate (to
mimic phosphorylation) residues at this position (Fig. 7A).
Proteins harbouring these mutations have previously been
shown to be refractory to phosphorylation by cyclin A±cdk2
and to affect interactions with bHLH proteins (19).
The ability of Id3(Ala) and Id3(Asp) to regulate DNA
binding by SAP(1±157) was compared (Fig. 7B). Both Id
proteins caused a decrease in ternary complex formation, but
Id3(Ala) was the most potent (Fig. 7B, compare lanes 2 and 4).
Consistent with this observation, SAP-1(1±157)±Id3(Asp)
fusion proteins also exhibited higher DNA-binding activity
than their alanine mutant counterparts (data not shown).
Next we compared the ability of mutant Id2±GST fusion
proteins to bind to SAP-1(1±157). Reduced binding of
SAP-1(1±157) was observed to Id2(Asp)±GST in comparison
with Id2(Ala)±GST (Fig. 7C). Similar results were obtained
for interactions with Elk-1(1±168) (data not shown). Finally,
we compared the ability of the Id2 mutants to interact with
full-length Elk-1 in vivo. Again, more binding of Elk-1 to
Id2(Ala) was observed than to Id2(Asp) (Fig. 7D, lanes 4 and
5). This is probably an underestimate of the difference due to
the higher expression levels of Id2(Asp) (Fig. 7D, middle
panel).
Figure 6. Effect of phosphorylation on Id2 interactions with Elk-1 in vitro.
(A) A ¯ow diagram depicting steps used to test binding of the Elk-1 ETS-
domain and Id2 is shown on the left. Id2 and the Elk-1 ETS-domain were
co-expressed in E.coli from a single plasmid. Induced protein complexes
were puri®ed and used in subsequent experiments. Puri®ed complexes were
either phosphorylated with cyclinA±Cdk2 or mock treated and immuno-
precipitated with Id2 antibody coupled to agarose beads (~1 mg of total puri-
®ed protein complex was used). After washing, the remaining Elk-1 in the
complex was detected by western blot using Flag antibody. Duplicate
samples are shown in lanes 1 and 2, and 3 and 4. Ten percent of the input
protein is shown. (B) GST pull-down analysis of the ETS-domain (amino
acids 1±93) of Elk-1 (1 mg) with 1.5 mg of GST (lane 1) or 1.5 mg of Id2±
GST fusion protein, with or without prior phosphorylation by cyclinA±Cdk2
(lanes 3 and 2, respectively). Lane 4 shows 10% of input protein. (C) GST
pull-down analysis of full-length Elk-1 (amino acids 1±428) with Id2±GST.
Elk-1 (220 ng) was left unphosphorylated (lanes 5±8) or phosphorylated
with Erk (lanes 1±4). Id2±GST (1.5 mg) was either non-phosphorylated
(lanes 1 and 5) or phosphorylated with cyclinA±Cdk2 (lanes 2 and 6). GST
(1.5 mg) was used as a control (lanes 3 and 7). Lanes 4 and 8 show 20% of
input. Precipitated Elk-1 was detected using anti-Flag antibody.
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To further con®rm the functional importance of Ser5
phosphorylation for Id function towards the TCFs, we carried
out transfection experiments in which we analysed the ability
of Id3 to inhibit transcription driven by a constitutively active
Elk-VP16 fusion protein. Wild-type Id3 was compared with
Id3(Ala), in which Ser5 is mutated to alanine and hence can no
longer be phosphorylated by cyclin±Cdk complexes (19). Elk-
VP16 strongly activated the SRE reporter gene (Fig. 7E). Co-
transfection with increasing amounts of wild-type Id3 led to a
decrease in transactivation. However, co-transfection with
Id3(Ala) led to an even greater inhibition of transactivation
which is most apparent at the highest concentrations of
expression vector used [20% reduction with wild-type Id3 and
>50% reduction with Id3(Ala)] (Fig. 7E). Importantly, the
expression levels of the wild-type and mutant Id3 proteins
were virtually identical at these concentrations (Fig. 7E, right
hand panel). These data therefore support the notion that
phosphorylation weakens interactions between Ids and the
TCFs and hence reduces their inhibitory activity.
In summary, mutation of Ser5 in the Id proteins leads to
effects consistent with the importance of this residue as a
phosphorylation-regulated switch that controls the inter-
actions between the Id proteins and TCFs and hence the
Id-mediated inhibitory properties.
DISCUSSION
DNA binding by ETS-domain transcription factors is a
tightly regulated process that often involves autoinhibitory
mechanisms [reviewed in Graves et al. (36)]. This autoinhibi-
tion is thought to stop promiscuous binding by these proteins
in the absence of appropriate regulatory cues or co-regulatory
partner proteins. Indeed, different members of the TCF
subfamily are regulated by multiple autoinhibitory mechan-
isms. For example, DNA binding by Elk-1 is regulated by a
combination of the B-box region and its C-terminal region
(10,11). DNA binding by SAP-2/Net/ERP is regulated by the
NID region (12). Here we show that the analogous NID region
of SAP-1 plays a major role in inhibiting its DNA-binding
activity (Fig. 1). In addition, the NIDs from both SAP-2/Net/
ERP and SAP-1 act as transcriptional repression domains
(Fig. 2) (12). These regions therefore are functionally
Figure 7. Phosphomimetics imitate phosphorylation of Id. (A) Schematic
illustration of a series of mutants of Ser5 in Id2 and Id3. (B) Gel retardation
analysis of in vitro translated SAP-1 (amino acids 1±157) in a ternary
complex (3o) with coreSRF and c-fos SRE. Complexes were challenged with
increasing amounts, 0.5 (lanes 2 and 4) and 2.5 ml (lanes 3 and 5), of
equimolar stocks of in vitro-translated Id3 Ala5 or Asp5 mutants. (C) GST
pull-down analysis of SAP-1(1±157) binding to the indicated mutant GST±
Id2 fusions. Lanes 1 and 2 [Id2(Ala)±GST], lanes 3 and 4 [Id2(Asp)±GST]
and lanes 5 and 6 (GST) represent duplicate samples; lane 7 shows 10% of
input. (D) Co-immunoprecipitation of Id2 mutants with Elk-1 from 293T
cells. Cells were either mock transfected with empty vector (lane 1) or
transfected with 7.5 mg of Elk-1 (lane 2), or 7.5 mg of Elk-1 and 7.5 mg of
either Id2(WT), Id2(Asp) or Id2(Ala) (lanes 3, 4 and 5, respectively). Elk-1
complexes were precipitated using anti-Flag antibody coupled to Sepharose
beads, and bound protein was detected by western analysis with Id2
antibody. Westerns with Id2 and Flag antibodies were used to compare
relative expression levels of Id2 and Elk-1 in the input samples (bottom two
panels). (E) Reporter gene analysis of Id-mediated inhibition of TCF
activity. Cells were co-transfected with 100 ng of pSRE-luc reporter vector,
100 ng of pCH110, 10 ng of pRSV-Elk-VP16 (lanes 2±7) and increasing
amounts of wild-type Id3 and Id3(Ala) (0.3, 1 and 3 mg) (indicated
schematically with a triangle under each set of bars). Data presented are
duplicate samples normalised with respect to b-gal activity, and values are
given relative to reporter alone (taken as 1). Protein expression levels in
whole-cell extracts of transfected cells were determined by western
analysis, using Id3-speci®c antibodies (right hand panel). Extracts were
analysed from samples taken from untransfected cells (lane 1) and cells
transfected with 3 mg of wild-type Id3 (lane 2) or Id3(Ala) (lane 3).
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equivalent in addition to exhibiting signi®cant sequence
similarity (Fig. 4A). Mutagenic studies on SAP-2/Net/ERP
provided evidence to underpin the idea that the NID contains a
HLH motif (12). Deletion analysis demonstrated that removal
of part of the C-terminal helix in the NID HLH motif
abrogated the inhibitory activity of this motif in SAP-1
(Fig. 1). Furthermore, the introduction of helix-breaking
proline residues into the putative helices of the HLHmotif also
abrogated the inhibitory activity of the NID (Fig. 4D), further
enhancing our conclusion that as in SAP-2/Net/Erp (12), this
region probably represents a HLH motif.
In addition to the NID, the N-terminal domain encompass-
ing the ETS-domain was identi®ed as a transcriptional
repression domain in SAP-1 (Fig. 2). This is consistent with
the observation that the equivalent region of Elk-1 has
repressive activity through recruiting the Sin3A/HDAC com-
plex (29). Elk-1 contains an additional repression domain, the
R-motif, that is not conserved in SAP-1 and SAP-2/Net/ERP
(37). In addition to the ETS-domain and NID, SAP-2/Net/ERP
contains a further repression domain, the CID, which is not
conserved in the other TCFs (38). Thus, each of the TCFs
appears to have acquired different negatively acting regions
that serve to modify their transcriptional activation properties.
The Id proteins act in trans to inhibit DNA binding of TCFs
through binding to the ETS DNA-binding domain (13). The
Ids exhibit signi®cant sequence similarity to the NID, but this
is restricted to the HLH motifs (Fig. 4A). Fusion of the Ids to
the TCFs inhibits their DNA-binding capacity (Fig. 4), and the
isolated SAP-1 NID acts in trans to inhibit the DNA-binding
activity of the TCF ETS-domain (Fig. 3). Furthermore, the
target for inhibition for both the NID and the Id proteins is
through the ETS-domain. Therefore, in addition to their
sequence conservation, the Ids and NID are functionally
equivalent in inhibiting DNA binding by TCFs whether
analysed in cis or in trans.
Phosphorylation of the Id proteins on Ser5 by cyclinA/E±
Cdk2 complexes reduces their ability to inhibit DNA binding
by the class A bHLH `E' proteins (18,19). Replacement of this
residue by the phosphomimetic aspartate causes a similar
effect (19). Here we show that phosphorylation of Id2 and Id3
reduces their potency as inhibitors of TCF DNA binding
(Fig. 5). This reduction in DNA-binding activity is mirrored
by reductions in protein±protein interactions between the Ids
and the TCFs (Fig. 6). Similarly, the replacement of Ser5 with
aspartate leads to a loss of inhibitory activity and interactions
with TCFs in vitro and in vivo (Fig. 7), but this appears to be a
weak phosphomimetic by comparison with the data obtained
with cyclinA±Cdk2 phosphorylated proteins. Low level
binding of phosphorylated Id2 to non-phosphorylated Elk-1
is still detectable, which is further reduced upon phosphoryl-
ation of Elk-1 (Fig. 6). Thus the active phosphorylated form of
Elk-1 appears refractory to Id binding and hence to inhibition
of its DNA binding. A potential role for the Id proteins is to
remove inactive TCFs from the promoter and permit exchange
with other TCFs. Indeed, evidence to support this is provided
by the observation that Id proteins cause the inhibition of TCF-
mediated transactivation (Fig. 7E) (13). The non-phosphoryl-
atable Ser5Ala mutant form of Id3 acts as a more potent
inhibitor, consistent with our conclusion that phosphorylation
causes disruption of Id±TCF complexes. Phosphorylation of
the Id proteins occurs at the G1/S phase boundary, which
would cause release of the TCFs to permit recycling of these
transcription factors. The observation that phosphorylation of
Id proteins causes the disruption of pre-formed Id±TCF
complexes and blocks the formation of new complexes
(Fig. 6A and B) provides further support for this model.
In summary, we have demonstrated the importance of the
HLH motifs in regulating the DNA-binding activities of the
TCFs both in cis and in trans, and uncovered further
complexities in how the inhibitory activities of the Id proteins
are regulated by phosphorylation.
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